

Supplementary Material

Additional Methods:

Our entire survey was piloted among 12 non-physicians, 6 rheumatologists, and 3 other physicians who provided valuable feedback regarding the clarity of questions and length, covering a range of ages from 19 years to mid-80s. Patients with incomplete questionnaires contributed data from questions which they answered; missing data is reported for individual covariates. This study was approved by the Hospital for Special Surgery Institutional Review Board. ICD-10 codes were used to identify patients with SRDs (Supplementary Table 1). We evaluated demographic baseline characteristics of survey respondents to non-respondents (Supplementary Table 2).

Supplementary Table 1. ICD-10 Algorithms Used to Identify Patients with Systemic Rheumatic Diseases (SRDs)	
SRD	ICD-10 Codes*
Rheumatoid arthritis	M05.x, M06.x
Polyarthritis-multiple sites, Type not Specified	M13.xx
Palindromic rheumatism	M12.3x
Behcets	M35.2
Systemic lupus erythematosus	M32.x
Systemic sclerosis	M34.x
Ankylosing spondylitis/sacroiliitis	M45.x
Inflammatory Spondyloarthropathy	M46.9x, M46.80, M46.82, M46.84, M46.86, M46.87, M46.88
Sjogren's/Sicca syndrome	M35.0x
Psoriatic arthritis	L40.5x
Juvenile Arthritis	M08.x
Mixed connective tissue disease	M35.8, M36.8
Undifferentiated Connective Tissue Disease	M35.9
Myositis	M33.x, G72.41, M36.0
Vasculitides	M30.x, M31.x, I77.6
Sarcoidosis	D86.x
Overlap syndrome	M35.1
Relapsing Polychondritis	M94.1
Diffuse eosinophilic fasciitis	M35.4
IgG4-related disease	M35.5
Autoinflammatory Syndromes	M04.x
Enteropathic arthritis-multiple sites, Inflammatory Arthritis Associated with IBD	M07.69, M07.6
Primary Antiphospholipid Syndrome	D68.61, D68.62, D68.3
Polymyalgia Rheumatica	M35.3
<i>*Algorithms required two codes within the same row \geq 7 days apart</i>	

Additional Results:

Respondents to our survey were slightly older (58.7 [14.2] versus 57.2 [16.5] years) and were more likely to be white (84.2% versus 78.3%) (Supplementary Table 2). Although the difference in age was statistically significant likely due to our large sample size, this difference was very small and not likely to be clinically meaningful. Given that fewer non-White patients responded, our survey may not be generalizable to non-White patients.

	Respondents N=1483	Non- Respondents N=2062	P-value**
Age in years, mean (SD)	58.7 (14.2)	57.2 (16.5)	<0.01
BMI, mean (SD)	26.8 (8.2)	26.6 (6.3)	0.41
Female	1213 (81.8)	1652 (80.1)	0.24
Race			<0.01
• White	1248 (84.2)	1614 (78.3)	
• Non-white*	192 (12.9)	387 (18.8)	
• Missing	43 (2.9)	61 (3)	
Ethnicity			0.71
• Hispanic/Latinx	115 (7.8)	167 (8.1)	
• Not Hispanic/ Latinx	1338 (90.2)	1846 (89.5)	
• Missing	30 (2)	49 (2.4)	
*Includes: American Indian/Alaskan Native/ Native Hawaiian/Other, Asian/ Indian Subcontinent, Black race			
**T-tests were used for continuous variables, Fisher's Exact tests were used for categorical variables. Missing values are reported but were not included in p-value calculations.			